The Indian stock market plunged over 1% for the second day in a row on Monday weighed down by US recession fears triggered risk-off sentiment.The S&P BSE Sensex plunged 2,223 points to close at 78,759 while the Nifty50 was down 668 points to close at 24,048. Market Roundup

Technical Breakout Stocks: Sun Pharma, Ajanta Pharma and JB Chemicals hit record high when Sensex falls 2,200 points - Market Roundup

Torrent Pharmaceuticals likely to acquire KKR’s stake in JB Chemicals for ₹17,000-18,000 crore, boosting chronic therapies portfolio.

Torrent Pharmaceuticals set to acquire KKR’s stake in JB Chemicals

Here is all you need to know about JB Chemicals’ ‘buy’ rating from Kotak Institutional Equities.

Stock Of The Day: JB Chemicals Surges After Kotak Initiates ‘Buy’

KKR & Co. is exploring options including selling its controlling stake in India’s JB Chemicals & Pharmaceuticals Ltd. amid interest from potential buyers, according to people familiar with the matter.

KKR Considers Selling Stake In India’s $3 Billion JB Pharma, Sources Say

Domestic revenue grew by 13.5% YoY to Rs 4.6 billion on the back of acquired brands, mid-teens growth in the chronic segment and recovery in the acute segment

JB Chemicals Q3 Results Review - Domestic Business, CMO To Drive Future Growth: Nirmal Bang

JB Chemicals and Pharmaceuticals Ltd. has completed five acquisition/in-licensing deals in the last two years in a bid to diversify its India revenue base.

JB Chemicals & Pharma - On M&A Spree To Diversify India Base: ICICI Securities

On a quarterly basis, JB Chemicals/Ajanta Pharma/Macleods/Sun Pharma outperformed IPM, while Mankind Pharma, Lupin underperformed.

India Pharma - IPM Growth On Moderate Uptrend In September: Motilal Oswal

“Whenever we have seen a change of management like this, it has worked positively for shareholders. Look at what happened in JB Chemicals, and even then UniChem. All the acquisitions which have taken place in the pharma industry have been very positive for both the acquirer as well as the acquired c…

4+1 stocks that Dipan Mehta would keep in his 5-year-plus basket

JB Chemicals & Pharmaceuticals on Wednesday received approval from the US health regulator to market a generic product, used to treat mood disorders, in the American market. The company’s product is the generic version of Pfizer’s Sinequan capsules which are indicated for the treatment of anxiety, d…

JB Chemicals gets USFDA nod to market generic medication

Double-digit growth in the domestic and international formulations segments helped JB Chemicals clock in robust numbers for the April-June quarter.

JB Chemicals scales 52-week high on 35% surge in Q1 net profit

Input cost decline not meaningful in recent months.

JB Chemicals - Normalised Growth To Dampen Earnings Flare Up; Downgrade To ‘Reduce’: Yes Securities

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets a range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredient (APIs).